NanoMedSyn is a start-up company arisen from the translational approach of three academic institutess based in Montpellier, France. After years of collaborative research, the founders, Dr M. Garcia, who laid the foundation of the project, Pr A. Morère , Drs M. Gary-Bobo and J-O Durand built together a new approach of therapeutic targeting to respond to unmet medical needs.
CEO and co-founder of NanoMedSyn
Dr M. Garcia was the research director of “glyco and nanovectors for therapeutic targeting” team, located in the IBMM (Montpellier). Based on strengths in glycochemistry, nanotechnology and biological system’s engineering, his research group developed innovative molecular technology to enable novel approaches to study, diagnose and treat diseases. He is expert in the field of hormone-dependent cancer and has had a pivotal role in the development of a diagnostic tool for breast cancer (ELSA-Cathepsin D) in collaboration with Sanofi. More recently, his research has been focused on the mechanism of lysosomal targeting and on the bioengineering of antibodies, enzymes and nanoparticles for new targeted therapies. After him academic carrier, Marcel joins NanoMedSyn as CSO in 2018 and as CEO in 2020 after the medical retirement of our beloved CEO Henry-Vincent Charbonné.
Professor, co-founder and scientific advisor of NanoMedSyn
Alain Morère is Professor of Chemistry at the University of Montpellier. His research work focuses on organic chemistry for the design and development of molecular tools dedicated to biological applications and processes. He is an expert in glycochemistry, development and synthesis of carbohydrate analogues and glyco-conjugates for cell targeting, receptor-ligand recognition, drug carriers and drug delivery.
CNRS researcher, co-founder and scientific advisor of NanoMedSyn
Dr Jean-Olivier Durand is an academic research director in the ICGM, Montpellier. Over the past 25 years, he has developed an expertise in the field of organic chemistry applied for healthcare. His research skills are focused on nanoparticles, which have been developed for peptidic micro-array, photodynamic therapy and also for photo-controlled drug delivery. He also has an interest on nucleic acids and the potential of transfection of nucleic acid with nanoparticles.
CNRS research director, co-founder and scientific advisor of NanoMedSyn
Dr Magali Gary-Bobo is a young academic CNRS researcher in biotechnologies and is co- founder of NanoMedSyn. During her research work, she has developed expertise in the drug delivery, lysosomal targeting for enzymotherapy and photodynamic therapy of cancers. Earlier in her career, she worked at Sanofi-Aventis, her work was involved in the development of Acomplia®, for obesity treatment.
Mabqi CEO and co-founder of several companies. Renowned expert in: Evaluation and transfer of industrial innovation.
Professor, Development Director Wyss Center, Campus Biotech (Geneva, Switzerland). Renowned expert in: Pharmaceuticals and biotechnology development.
Research director at CNRS. Renowned expert in: Baculovirus expression system, recombinant protein engineering and therapy.
Professor, Inserm / Hopital Necker -Enfants Malades. Renowned expert in: Inherited metabolism disorders and lysosomal storage disorders.
Amine A. Kamen
Professor, Canada research chair in bioprocessing of viral vaccines. Renowned expert in: Protein engineering and nanoparticles for drug delivery.